Estudo randomizado | Entre pacientes internados com COVID-19 sob risco de tromboembolismo venoso, a tromboprofilaxia pós-alta hospitalar com rivaroxabam por 35 dias pode melhorar os desfechos.

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Comentário convidado: Anticoagulation in COVID-19 – The Lancet

Comentário no Twitter

NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE trial https://t.co/OWcmjCLBTw pic.twitter.com/3Bl4lV16Va

— The Lancet (@TheLancet) December 16, 2021